Targets › MAP3K8
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Jan 2027.
Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the pro-inflammatory cytokine TNF (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. (UniProt, P41279)
Open in Phaseline: the race on MAP3K8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gilead Sciences | Tilpisertib Mitogen-activated protein kinase kinase kinase 8 inhibitor | MAP3K8 | Phase 2 | Ulcerative Colitis | Jan 2027 |
Ulcerative Colitis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.